Company Overview and News
KUALA LUMPUR: Pasdec Holdings Bhd , Barakah Offshore Petroleum Bhd , Revenue Group Bhd, Orion IXL Bhd and Kerjaya Prospek Group Bhd are among the stocks to watch on Friday, according to JF Apex Research.
KUALA LUMPUR (Oct 11): Based on corporate announcements and news flow today, stocks in focus on Friday (Oct 12) may include Pasdec Holdings Bhd, Barakah Offshore Petroleum Bhd, Top Glove Corp Bhd, Revenue Group Bhd, Ta Win Holdings Bhd, Cuscapi Bhd, Supermax Corp Bhd, Orion IXL Bhd and Kerjaya Prospek Group Bhd.
6912 TGLVY SPMXY 7251 7097 SPMXF BKKLF 7113 TPGVF BSMAF 1818
KUALA LUMPUR (Oct 11): Pasdec Holdings Bhd’s indirect subsidiary Pasdec Automotive Technologies (Botswana) (Pty) Ltd has secured a RM380 milion contract from Nissan South Africa (Pty) Ltd.
6912 BSMAF 1818
KUALA LUMPUR: AirAsia Bhd , Kuala Lumpur Kepong Bhd , Hock Seng Lee Bhd (HSL), Pasdec Holdings Bhd , Scomi Group Bhd and Tan Chong Motor Holdings Bhd are among the stocks to watch, according to JF Apex Research.
6912 KLKBY 2445 EXPE 6238 4405 7158
KUALA LUMPUR (Aug 14): Based on corporate announcements and news flow today, stocks in focus tomorrow may include: AirAsia Group Bhd, Batu Kawan Bhd, Kuala Lumpur Kepong Bhd, DKSH Holdings (M) Bhd, Hock Seng Lee Bhd, IHH Healthcare Bhd, Nestlé (Malaysia) Bhd, Pasdec Holdings Bhd, Scomi Group Bhd, Tan Chong Motor Holdings Bhd, Versatile Creative Bhd and YTL YTL Hospitality REIT.
SLLXF 7158 532843 DKSHY 6912 KLKBY 2445 4995 EXPE 5225 FORTIS 6238 5109 4405 1899 Q0F IHHHF 5908 DKSHF
KUALA LUMPUR (Aug 14): Major shareholder Datuk Seri Tew Kim Thin has failed in his bid to take over Pasdec Holdings Bhd via his private vehicle Jasa Imani Sdn Bhd.
6912 BSMAF 1818
KUALA LUMPUR (Aug 3): Pasdec Holdings Bhd shareholders have been told to reject the takeover bid launched by its substantial shareholder Datuk Seri Tew Kim Thin, which has been deemed "not fair and not reasonable" by independent adviser Public Investment Bank Bhd (PIVB).
6912 BSMAF 1818
KUALA LUMPUR: Pasdec Holdings Bhd 's minority shareholders have been advised to reject a takeover offer from its major shareholder Datuk Seri Tew Kim Thin as the offer price of 52.5 sen was “not fair” and “not reasonbable”.
KUALA LUMPUR (July 16): Based on corporate announcements and news flow today, companies that may be in focus on Tuesday (July 17) may include the following: DBE Gurney Resources Bhd, KLCC Stapled Group, Salcon Bhd, TFP Solutions Bhd, Pasdec Holdings Bhd, GHL Systems Bhd, Nova MSC Bhd and Xinghe Holdings Bhd.
6912 0145 0026 BSMAF 0095 0021 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...